Insider Selling: Phreesia, Inc. (NYSE:PHR) SVP Sells 604 Shares of Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 604 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $26.98, for a total value of $16,295.92. Following the completion of the sale, the senior vice president now owns 115,029 shares in the company, valued at $3,103,482.42. This represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Amy Beth Vanduyn also recently made the following trade(s):

• On Monday, January 6th, Amy Beth Vanduyn sold 1,311 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $34,885.71.
• On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The stock was sold at an average price of $20.93, for a total transaction of $532,605.71.

Phreesia Stock Up 1.6 %

PHR opened at $27.24 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock’s fifty day moving average is $23.42 and its two-hundred day moving average is $22.77. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.58) earnings per share. As a group, analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Trust Point Inc. lifted its position in shares of Phreesia by 3.5% in the 3rd quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock worth $408,000 after purchasing an additional 607 shares during the period. Ensign Peak Advisors Inc raised its stake in Phreesia by 3.2% in the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after buying an additional 700 shares in the last quarter. Rhumbline Advisers lifted its holdings in Phreesia by 1.0% during the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after buying an additional 853 shares during the period. The Manufacturers Life Insurance Company boosted its position in Phreesia by 3.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after acquiring an additional 905 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Phreesia by 3.8% in the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after acquiring an additional 1,120 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Citigroup boosted their price objective on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Robert W. Baird lowered their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of Phreesia in a research report on Friday, January 10th. Finally, Truist Financial raised their price target on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $31.00.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.